CAR-T cell therapy has the characteristics of self-expansion and higher sensitivity to low antigen expression, thus having the potential to become a promising alternative strategy for targeting fibroblast activation protein (FAP) tumor stromal cells. The gene discussed is FAP; the disease is neoplasm.